Insights into HER2 signaling from step-by-step optimization of anti-HER2 antibodies.
Fu, W., Wang, Y., Zhang, Y., Xiong, L., Takeda, H., Ding, L., Xu, Q., He, L., Tan, W., Bethune, A.N., Zhou, L.(2014) MAbs 6: 978-990
- PubMed: 24838231 
- DOI: 10.4161/mabs.28786
- Primary Citation of Related Structures:  
3WSQ - PubMed Abstract: 
HER2, a ligand-free tyrosine kinase receptor of the HER family, is frequently overexpressed in breast cancer. The anti-HER2 antibody trastuzumab has shown significant clinical benefits in metastatic breast cancer; however, resistance to trastuzumab is common ...